drugset / Trial / NCT07015190
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Timeline
- Start
- 2026-01-25
- Primary completion
- 2030-10
- Completion
- 2031-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darovasertib | Small molecule | — | Oral |